LY9

Across TCGA pan-cancer cohorts, LY9 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LY9 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LY9 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LY9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD and HNSC are the cancer types where LY9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.848	0.372	.008	7	view →
HNSC	DFS	Tertile	All	0.832	0.274	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LY9–LUAD (OS)

Open the LUAD breakdown →